Therefore, it is an open question whether the optimal treatment for metastatic ALK-positive patients with NSCLC is starting with a second-generation ALK TKI and switching to a more potent, third-generation ALK TKI at progression in a sequential way or starting with a third-generation TKI as the first-line treatment. The gene discussed is ALK; the disease is non-small cell lung carcinoma.